MiMedx Group, Inc. — FY2020 Form 10-K Summary
Business Context and Reporting Period
MiMedx develops and sells placental-tissue allografts for advanced wound care, burn, surgical, and non-operative sports medicine applications. The company also has a late-stage pipeline centered on AmnioFix Injectable for musculoskeletal conditions. The filing covers the fiscal year ended December 31, 2020; fourth-quarter 2020 results are included in the quarterly data.
MiMedx operates as one reporting segment and is primarily U.S.-focused. Its common stock was relisted on Nasdaq in November 2020 after being delisted in March 2019 for failure to remain current with SEC filings.
Financial Performance and Liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Net sales | $248.2 million | $299.3 million | Down 17.0% |
| Gross profit | $208.9 million | $256.2 million | Down 18.5% |
| Gross margin | 84.2% | 85.6% | Down 140 basis points |
| Operating loss | $45.4 million | $21.2 million | Loss increased |
| Net loss | $49.3 million | $25.6 million | Loss increased 92.7% |
| Net loss per common share | $0.77 | $0.24 | Loss increased |
| Adjusted net sales | $240.5 million | $269.7 million | Down 11.0% |
| Adjusted EBITDA | $30.6 million | $42.1 million | Down 27.2% |
| Cash used in operating activities | $30.3 million | $39.4 million | Use decreased |
The reported 2020 net loss included $59.5 million of investigation, restatement, and related expenses, an $8.2 million loss on extinguishment of debt, $7.9 million of net interest expense, and a $12.3 million income tax benefit primarily associated with CARES Act net operating loss carrybacks. Fourth-quarter net sales were $68.5 million and net loss was $16.6 million.
Cash and cash equivalents were $95.8 million at December 31, 2020, compared with $69.1 million at December 31, 2019. Working capital was $101.5 million, and the current ratio was 2.7 to 1. Investing cash outflows were $4.6 million, while financing activities generated $61.6 million.
At year-end, debt consisted principally of a $50.0 million senior secured Hayfin term loan, recorded net at $47.7 million. The loan bears interest at 8.3% at year-end and matures June 30, 2025, with no scheduled principal payments before maturity. A separate $25.0 million delayed-draw facility was committed but undrawn. The company reported a 3.1x total net leverage ratio and was subject to a $10 million minimum liquidity covenant.
Material Changes Versus the Prior Comparable Period
- Sales declined primarily because of COVID-19-related restrictions, lower elective procedures, hospital cost controls, and the impact of revenue-recognition changes. Adjusted net sales declined 11.0%, excluding the transition effects.
- Gross margin fell to 84.2% from 85.6%, principally because of costs associated with higher CGMP quality standards.
- SG&A declined 8.7% to $181.0 million due partly to temporary salary reductions, lower travel, lower commissions, and lower professional fees.
- Investigation, restatement, and related expense declined to $59.5 million from $66.5 million, but remained a significant burden.
- Research and development expense increased 5.2% to $11.7 million as clinical and consulting costs increased.
- The company completed a $100 million Series B preferred-stock financing and borrowed $50 million under the Hayfin facility. Proceeds were used substantially to refinance prior Blue Torch debt and support working capital and investment.
- The Series B preferred stock accrued approximately $2.0 million of dividends in arrears at year-end and was convertible into approximately 26.5 million common shares, including accrued dividends, subject to the instrument’s terms.
- The company paid $6.5 million to settle a DOJ and VA-related pricing matter and paid $7.4 million to settle legal proceedings during 2020. Legal and other loss contingencies totaled $10.0 million at year-end.
- The company recorded a $0.8 million fourth-quarter out-of-period adjustment that increased fourth-quarter net sales and gross profit and reduced quarterly net loss by $1.3 million.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects 2021 adjusted net sales to increase at least 10% over 2020 adjusted net sales, assuming continued ability to sell micronized, particulate, and umbilical-cord products for the full year. This is management guidance, not a guarantee.
- Management anticipates research and development expense could increase by as much as three times in 2021 as it advances clinical trials, files additional INDs, and works toward BLAs.
- FDA enforcement discretion for certain products classified as Section 351 biologics was scheduled to expire May 31, 2021. Micronized and particulate products generated $32.8 million of 2020 revenue, while umbilical-cord products generated $16.6 million. Management estimated that removal of micronized and particulate products could reduce expected 2021 sales by approximately $20 million to $25 million.
- MiMedx was pursuing BLAs for certain micronized products and conducting trials for plantar fasciitis, Achilles tendonitis, and knee osteoarthritis. No BLA had been submitted for review as of the filing date, and approval remains uncertain.
- The company was transitioning manufacturing facilities toward CGMP compliance. A December 2019 FDA inspection of the Kennesaw facility resulted in a VAI classification; the Marietta inspection had not yet been categorized as of the filing.
- COVID-19 affected customer access, elective procedures, donor-tissue sourcing, and clinical-trial enrollment. Further waves, variants, or healthcare-system restrictions could adversely affect revenue, operations, and liquidity.
- Management concluded that disclosure controls and internal control over financial reporting were ineffective at December 31, 2020 because of material weaknesses involving revenue, inventory, income taxes, payables, forecasting, goodwill impairment, accrued expenses, and related control activities. BDO issued an adverse opinion on internal control over financial reporting, although it issued an unqualified opinion on the financial statements.
- The company remains exposed to securities litigation, government investigations, indemnification claims involving former officers, and other legal matters. A February 2021 Department of Defense subpoena concerning federal sales, micronized products, and FDA communications remained unresolved at the filing date.
- The 2020 FDA Class II recall involving tissue recovered from four Florida donors had resulted in no reported adverse reactions as of the filing date.
Most Important Facts for Investors to Verify
- Whether the company maintained compliance with Hayfin leverage and minimum-liquidity covenants as regulatory and commercial conditions changed.
- The FDA’s treatment of micronized, particulate, and umbilical-cord products after the May 31, 2021 enforcement-discretion period, including any required market withdrawals or approvals.
- Progress, results, and FDA feedback from the AmnioFix Injectable clinical programs and the timing and feasibility of any BLA submissions.
- Whether management fully remediated the material weaknesses in internal control and disclosure controls.
- The ultimate cost and resolution of securities litigation, government investigations, indemnification obligations, and other contingencies beyond the $10.0 million accrued reserve.
- The sustainability of adjusted net sales growth, gross margins, and adjusted EBITDA after excluding investigation, restatement, revenue-recognition, and other non-GAAP adjustments.
- The potential dilution and cash obligations associated with Series B preferred-stock conversion, accrued dividends, and change-of-control redemption rights.